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Abbreviations
and Acronyms
BNP = brain natriuretic
peptide
ce-CMR = contrast-
enhanced cardiac magnetic
resonance
ECG = electrocardiogram
ICD = implantable
cardioverter-deﬁbrillator
IHD = ischemic heart
disease
LVEF = left ventricular
ejection fraction
NT proBNP = N-terminal pro
brain natriuretic peptide
NYHA = New York Heart
Association
PVC = premature ventricular
complex
RFCA = radiofrequency
catheter ablation
SHD = structural heart
disease
SOO = site of origin
SSA = successful sustained
ablation
VT = ventricular tachycardia
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1196in patients with a suspected
PVC-induced cardiomyopathy
(1–6). The ablation of frequent
PVC in a small series of
15 patients with ischemic heart
disease (IHD) improved LVEF
in comparison with a control
group of patients without ablation
(7). Similarly, RFCA of PVC
improved LVEF and NYHA
class in nonresponders to cardiac
resynchronization therapy (8).
However, the relationship be-
tween the degree of clinical beneﬁt
and a diagnosis of structural heart
disease (SHD) has not been
studied. Moreover, patients with
suspected PVC-induced cardio-
myopathy are followed up for
3 to 6 months after RFCA in
most studies; the temporal pattern
of improvement after ablation
of frequent PVC has not been
studied in depth (9).
The aim of the study was to
assess the clinical beneﬁt and
temporal recovery pattern after
ablation of frequent PVC in an
unselected group of consecutivepatients with LV dysfunction, regardless of the PVC origin
or SHD presence and etiology.
Methods
This multicenter, prospective, observational study was con-
ducted from February 2010 to January 2012. A total of 80
consecutive patients with LV dysfunction (deﬁned as
LVEF 50%) of any etiology and frequent and/or symp-
tomatic PVC accepted for RFCA were included at the four
participating centers. Frequent PVC was deﬁned as a burden
of more than 4% at baseline 24-h Holter monitoring, which
is the lowest reported PVC burden associated with tachy-
cardiomyopathy in the literature (10). No patient was
excluded because of the number of PVC morphologies or
the presumed site of origin (SOO) based on electrocardi-
ography (ECG) criteria.
Baseline evaluation. A detailed medical and drug history
and a blood test, including neurohormonal evaluation (brain
natriuretic peptide [BNP] in 3 centers and N-terminal pro-
brain natriuretic peptide [NT proBNP] in 1 center) were
obtained for all participants. All patients had a 12-lead
surface ECG and Holter monitoring prior to the ablation
procedure to evaluate the presence of multiple morphologies
and to calculate the PVC burden. Baseline echocardiography
was performed within the 4 months preceding the RFCA
procedure. LVEF was calculated by the Simpson formula(i.e., 3 consecutive beats averaged to minimize distortion
generated by PVC). When logistically possible and in the
absence of contraindication, a contrast-enhanced cardiac
magnetic resonance (ce-CMR) was obtained and analyzed
to determine the presence of myocardial scar. Acquisition
and post-processing methods are described in the Online
Appendix (11).
Ablation procedure. Before the ablation, antiarrhythmic
drugs except amiodarone were withdrawn for 5 half-
lives. Ablation was guided by the Carto navigation system
(Biosense-Webster, Waterloo, Belgium). Intravenous infu-
sion of isoproterenol was used if the patient had no spon-
taneous PVC at baseline. All PVC morphologies thought to
contribute to the LV dysfunction, based on 4% burden in
Holter monitoring and the operator’s clinical judgment
during the procedure, were targeted for ablation. A 3.5-mm
irrigated-tip catheter (Navi-Star, Biosense Webster) was
used for mapping and ablation. Radiofrequency application
was guided by activation mapping in 44 patients, pace
mapping in 2 patients, and a combination of both tech-
niques in 34 patients. Acute successful ablation was con-
sidered when targeted PVC were eliminated and were
noninducible after isoproterenol infusion. Patients were
monitored for 30 min after the procedure to ensure complete
PVC abolition. Programmed stimulation to induce ven-
tricular arrhythmias was not part of the study protocol and
was only performed in selected patients, at the operator’s
discretion. In case of acute successful ablation, amiodarone
was discontinued. As the entire population of the study
had LV dysfunction, therapy with beta-blocker (90%) and
angiotensin-converting enzyme inhibitor was maintained
independently of the ablation success.
Follow-up. Patients were attended at an outpatient clinic.
Scheduled visits at 1, 6, and 12 months post-ablation
included evaluation of functional class and a blood test
with BNP determination. In one center, NT pro-BNP was
obtained at 3 months.
A 24-h Holter ECG was obtained at 6 and 12 months.
Successful sustained ablation (SSA) was deﬁned as the
persistent elimination of at least 80% of PVC after a ﬁrst
ablation procedure with no recurrences after 12 months of
follow-up. Nonsustained ventricular tachycardia (VT) was
deﬁned as VT (>100 beats/min) of 3 beats that self-
terminates within 30 s. Echocardiography was repeated at
6 and 12 months. Echocardiographic response was deﬁned
as an absolute increase in LVEF of 5% after RFA, as in
clinical trials on CRT implantation and previous PVC
ablation series (10,12).
Statistical analysis. Continuous variables are presented as
the mean  SD. BNP and NT-proBNP are presented as the
median and interquartile range due to their skewed distri-
butions. Categorical variables are presented as total number
and percentages. To compare means of 2 variables, Student t
test was used (or Wilcoxon when necessary). Proportions
were compared using chi-squared or Fisher exact test, as
appropriate. Friedman analysis of variance by ranks was used
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1197for repeated measures. Logistic regression analysis was used
to study the effects of baseline characteristics in predicting
echocardiographic response, acute successful ablation, and
SSA. A p value <0.10 was used to screen covariates for
inclusion in the multivariate analysis. A backward stepwise
selection algorithm was applied to select covariates for
inclusion in the multivariate regression model. At each step,
the least signiﬁcant variable was discarded from the model.
Odds ratio (OR) and 95% conﬁdence interval (CI) were
calculated. Receiver-operating characteristic (ROC) curve
analysis was used to evaluate the optimal cutoff value
for predicting echocardiographic response. A p value <0.05
was considered statistically signiﬁcant. Statistical analysis
was performed using R software for Windows version 2.15.0
(R Project for Statistical Computing, Vienna, Austria).
Results
Eighty consecutive unselected patients (47 men; mean
age: 53  12 years) were included. Follow-up was not
available for 3 patients because of 1 noncardiac death,
1 change of residence, and 1 recent diagnosis of disabling
neurological disease. Mean LVEF was 34.3  13%, with
22  13% mean PVC burden in the Holter monitoring
(Table 1). Before the ablation, an attempt to suppress PVC
was ineffective with beta-blocker in 56 patients, amiodarone
in 1 patient, and a combination of both in 16 patients.Table 1 Baseline Characteristics
No SHD
(n ¼ 53)
Age, yrs 51.5  11.7
Male 25 (47)
LVEF, % 34.7  7.8
LVESD, mm 44.5  6.8
LVEDD, mm 59.3  6.0
Treatments, %
Beta-blocker 92
ACEI 81
Spironolactone 53
Amiodarone 23
PVC Holter
% 18  12
n/24 h 17,237  11,109
NYHA class
I 12 (23)
II 31 (58)
III 10 (19)
IV 0
Hyperenhancement, % of patients 5.7
BNP, pg/ml 109 (47–340)
NP pro-BNP, pg/ml 228 (65–431)
(n ¼ 10)
Values are mean  SD, n (%), or median (range).
ACEI ¼ angiotensin-converting enzyme inhibitor; BNP ¼ brain natriuretic
ventricular ejection fraction; LVESD ¼ left ventricular end-systolic diameter; N
Heart Association; PVC ¼ premature ventricular complex; SHD ¼ structural hDyspnea and palpitations were the dominant presenting
symptom in 58 (74%) and 38 (48%) patients, respectively.
Only 12 (15%) patients were asymptomatic at the time of
ablation. Five patients with SHD had an implantable car-
dioverter-deﬁbrillator (ICD) for secondary prevention at the
time of ablation, 3 of them due to spontaneous sustained VT
and 2 because of syncope. Two patients had a pacemaker
because of prior atrioventricular block. In all patients
without previously diagnosed SHD, IHD was ruled out by
coronary angiography or noninvasive stress test before the
ablation procedure.
Twenty-seven patients (34%) had previously diagnosed
SHD. Seventeen had ischemic heart disease, 2 valvular heart
disease, 4 noncompaction cardiomyopathy, and 1 case each
of hypertensive cardiomyopathy, peripartum puerperal
cardiomyopathy, tetralogy of Fallot, and arrhythmogenic
right and left ventricular dysplasia (Table 1). Most patients
with previously diagnosed SHD had received that diagnosis
before they were considered for PVC ablation, except 2
patients with noncompaction cardiomyopathy in whom
a ﬁnal diagnosis was established by the pre-procedural ce-
CMR. Ten of the 17 (59%) ischemic patients had prior
myocardial infarction and 7 (41%) additional patients had
signiﬁcant coronary artery disease and prior revascularization
without myocardial infarction.
In total, 96 PVCs were targeted for RFCA. Twenty
(25%) patients had more than one PVC morphology in theSHD
(n ¼ 27)
All Patients
(N ¼ 80) p Value
56.6  11.4 53  11.8 0.065
22 (82) 47 (59) 0.003
33.5  8.9 34.3  13 0.54
45.7  7.0 44.9  6.9 0.48
61.0  6.9 59.9  6.3 0.21
85 90 0.32
85 83 0.66
30 51 0.005
19 21 0.67
29.8  13.0 22  13 <0.001
27,154  16,971 20,326  13,863 0.009
0.19
9 (33) 21 (26)
10 (37) 41 (51)
8 (30) 18 (23)
0 0
33 15 <0.001
107 (85–217) 109 (81–905) 0.94
570 (110–938)
(n ¼ 7)
259 (97–905)
(n ¼ 17)
0.33
peptide; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼ left
T pro-BNP ¼ N-terminal pro brain natriuretic peptide; NYHA ¼ New York
eart disease.
Table 2
Site of Origin of the 96 PVCs Targeted for Ablation
and the Number Involving Patients With SHD
[in Brackets]
Left Ventricle Right Ventricle Epicardium
Outﬂow tract:
8 left coronary sinus
of Valsalva [2]
Outﬂow tract:
24 septal [2]
Left ventricle summit:
5 [2]
8 right coronary sinus
of Valsalva [1]
15 lateral [2]
3 subvalvular [2]
Infarct scars:
8 septal [8]
3 apical [3]
3 lateral [3]
Parahisian:
2 [1]
Cardiac venous system:
6 [2]
Papillary muscle:
5 [5]
Mitral annulus:
2 [2]
Tricuspid annulus:
2 [0]
Epicardial scar:
1 [1]
Right coronary sulcus groove:
1 [1]
Abbreviations as in Table 1.
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1198baseline Holter monitoring. In 9 of them (4 ischemic and
5 without previous SHD), at least 2 different PVC mor-
phologies were targeted for ablation; only the “dominant”
PVC was targeted in the remaining 11 patients. Table 2
shows the site of origin (SOO) of targeted PVCs.Figure 1 Recovery Pattern After Radiofrequency Ablation In Patients
The temporal recovery pattern of brain natriuretic peptide (BNP)/N-terminal pro brain natr
Heart Association (NYHA) functional class, and the reduction in premature ventricular com
for the PVC burden. Most of the beneﬁt was obtained in the ﬁrst 6 months. Gray bars ¼ no
during follow-up. SHD ¼ structural heart disease; SSA ¼ sustained successful ablation.Acute successful ablation was achieved in 68 patients
(85%). Complications occurred in 4 patients (5%): 1
uncomplicated hematoma in the puncture site, 1 episode of
pericarditis, 1 pulmonary thromboembolism, and 1 episode
of periprocedural tamponade resolved without further
complications.
Follow-up. Mean follow-up was 11.2  2.4 months. PVC
recurred in 15 of 68 patients (22%) with acute successful
ablation, in 14 (93%) of them within 6 months. Therefore,
SSA was achieved in 53 patients (66%).
Echocardiographic response. In patients with SSA, LVEF
improved from 33.7  8% at baseline to 43.8  9.4% and
45.8  10.9% at 6 and 12 months, respectively (p < 0.05).
Interestingly, most (84  39%) of the beneﬁt was obtained
in the ﬁrst 6 months (Fig. 1). Accordingly, left ventricular
end diastolic diameter decreased from 59.5  5.9 mm to
56.3  5.3 mm at 6 months and 54.9  6.1 mm at
12 months (p < 0.05). Left ventricular end systolic diameter
decreased from44.4 6.2mm to 39.9 5.3mmand 39 6.9
mm at 6 and 12 months, respectively (p < 0.05).
There was a close relationship between the percentage of
PVC at baseline and echocardiographic response (Fig. 2).
When SSA was achieved, a baseline PVC burden 13% hadWith and Without Previously Diagnosed SHD and With SSA
iuretic peptide (NT pro-BNP) levels, left ventricular ejection fraction (LVEF), New York
plex (PVC) burden is shown. There were no signiﬁcant differences at baseline except
SHD; black bars ¼ SHD. *p < 0.05 versus baseline. p< 0.05 versus previous value
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Figure 2 Echocardiographic Response
The relationship between the baseline PVC percentage during Holter monitoring and the LVEF improvement during follow-up. Green ¼ no patient with a PVC burden <13%
improved after radiofrequency ablation. Pink ¼ most of the patients without beneﬁt and with a PVC burden 13% are without SSA. Abbreviations as in Table 1.
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1199a sensitivity of 100% and a speciﬁcity of 85% (area under
the curve: 0.87; CI: 0.72 to 1) to predict an absolute increase
of at least 5% of LVEF. Echocardiographic response was
observed in 88.3% of patients with 13% PVC and SSA.
In these patients, LVEF improved from 32.6  8.7% at
baseline to 48.8  7.2% and 51.9  7.1% at 6 and
12 months, respectively (p < 0.05). No patient with <13%
PVC at baseline improved after ablation.
At baseline, 29 patients (36%) with 13% PVCs met the
indication criteria for primary prevention ICD implantation
(13). In 20 patients (69%), SSA was achieved and at
6 months post-ablation, none of whom had any ICD indi-
cation. In 5 additional patients, the PVC burden was
reduced between 50% and 80% from baseline, LVEF
improved, and there were no indications for ICD implant at
6 months (n ¼ 3) and 12 months (n ¼ 2). Of the remaining
4 patients, 3 received an ICD and the fourth did not because
of comorbidity criteria. No sudden deaths or life-threatening
ventricular tachycardias occurred during the entire follow-up.
Neurohormonal response. In patients with SSA, there
was a signiﬁcant reduction in BNP levels from 109 (64 to 242)
pg/ml at baseline to 60 (25 to 170), 50 (14 to 130), and 60
(19 to 81) pg/ml at 1, 6, and 12 months, respectively
(p ¼ 0.004). NT pro-BNP levels showed the same reduction
pattern over time from 259 (90 to 907) pg/ml at baseline to
53 (29 to 337), 50 (28 to 330) pg/ml, and 49 (29 to 708) pg/ml
at 1, 6, and 12 months, respectively (n ¼ 17; p ¼ 0.112)
(Fig. 1). Notably, most of the reduction was obtained in the
ﬁrst month.
Clinical response. In patients with SSA, NYHA class
improved during the follow-up from only 12 patients (23%)
with NYHA I at baseline to 15 (28%), 42 (79%), and
42 (79%) at 1, 6, and 12 months, respectively (p < 0.001).Improvement in LVEF was directly related to the temporal
pattern of functional recovery.
ce-CMR. A ce-CMR study was available for 59 patients.
Hyperenhancement was present in 11 (19%) of them. Eight
(66%) of the 12 ischemic patients in whom a ce-CMR was
available had hyperenhancement in the ce-CMR study. In
patients with hyperenhancement, the mean scar mass was
9.23  8.4 g. There was no signiﬁcant difference in echo-
cardiographic response rate between patients with or without
hyperenhancement (LVEF improvement 12  7.6% and
9.6  12.3%, respectively; p ¼ 0.56). Patients with hyper-
enhancement had a greater baseline PVC burden (30  13.7
vs 17.5  10.7; p ¼ 0.001) and a greater absolute reduction
of PVC percentage after SSA (29.8  11.9 vs 15.5  10.6;
p ¼ 0.003). Interestingly, the SOO was not related to the
hyperenhanced areas in 7 (54%) of the 13 PVCs ablated in
patients with scar in the ce-CMR.
Previously diagnosed SHD. There is an association
between previously diagnosed SHD and LV origin (78% of
the patients with a previously diagnosed SHD had a LV site
of PVC origin vs 26% in patients without; p < 0.001). In
patients with previously diagnosed SHD, the PVC burden
was signiﬁcantly higher at baseline (Fig. 1) and the reduction
of PVC after SSA was more pronounced as compared
to patients without SHD (absolute reduction of PVC
percentage: 16  11% in patients without SHD, 28  13%
in patients with SHD; p ¼ 0.002). There was no difference
in echocardiographic response between patients with known
SHD and idiopathic LV dysfunction (mean absolute LVEF
improvement during follow-up, 13.5  11.8% vs 12  13%,
respectively; p ¼ 0.691). Accordingly, there was no differ-
ence in neurohormonal response (mean improvement in
BNP levels: 56 [5 to 143] pg/ml without SHD vs 87 [33 to
Table 3
Echocardiographic, Neurohormonal, and Clinical
Response After Ablation in Patients With and
Without Successful Sustained Ablation
SSA
(n ¼ 53)
No SSA
(n ¼ 27) p Value
LVEF improvement after
RFCA, %
12.6  12.4 5.1  6.7 0.007
BNP reduction after
RFCA, pg/ml
87 (20 to 131) 22 (–17 to 37) 0.14
NP pro-BNP reduction
after RFCA, pg/ml
123 (44–368) 25 (–98 to 120) 0.12
Patients with NYHA II
or higher at baseline
and a decrease of
1 or more NYHA class
after RFCA
36 (94) 11 (60) 0.003
Values are mean  SD, median (95% conﬁdence interval), or n (%).
RFCA ¼ radiofrequency catheter ablation; SSA ¼ sustained successful ablation; other abbrevi-
ations as in Table 1.
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1200130] pg/ml SHD, p ¼ 0.79; mean improvement in NT pro-
BNP levels: 63 [36 to 240] pg/ml without SHD vs 183 [117
to 340] ml SHD; p ¼ 0.655) or in clinical improvement
during follow-up after SSA (symptomatic patients with
a decrease of at least 1 category of NYHA class during
follow-up: 27 (96%) without SHD vs 9 (90%) with SHD;
p ¼ 0.462).
Unsuccessful ablation. In 27 patients (34%), SSA was
not achieved; the ablation attempt was unsuccessful in
12 patients (15%) and PVC recurred during follow-up in 15
(19%) additional patients. Recurrent PVC was different
than that previously ablated in 2 patients (17%) without
SHD and in 2 patients (67%) with SHD.
Patients without SSA showed less improvement in
LVEF, rate of clinical response, and BNP/NT pro-BNP
reduction (Table 3). However, 7 patients with no SSA
were clinical responders (Fig. 2). In 5 of these patients, PVC
recurred but the PVC burden was decreased by 50% to 80%.
In the other 2 patients, PVC elimination was obtained with
antiarrhythmic drugs. In 4 patients, a second ablation
procedure was performed and 2 of them recurred.
Patients without SSA more frequently had nonsustained
VT during the follow-up Holter monitoring (48% vs 11%;Table 4 Predictors of Echocardiographic Response, Univariate and M
Response No Response O
Male, % 71.4 42.8 3.3
Age, yrs 53.7  12.3 52.6  11.4 1.0
Baseline PVC burden, % 29  9.7 15.4  13 1.1
QRS width, ms 170  19 174  18 0.9
Location, left ventricle, % 44.7 81.8 1.0
Location, epicardial, % 20.0 11.4 1.6
SSA, % 76.2 57.1 2.4
SHD, % 40.5 28.6 1.7
Scar size, g 1.56 1.57 0.9
Values are % or mean  SD.
OR ¼ odds ratio; other abbreviations as in Tables 1, 2, and 3.p ¼ 0.001), although none of the patients had life-
threatening arrhythmias.
Age, more than 1 PVC morphology at baseline, and
epicardial origin were associated with failure to achieve
SSA. In the multivariate analysis, only epicardial origin
independently predicted failure in achieving SSA (OR: 4.2;
95% CI: 1.1 to 16.4; p ¼ 0.042). Age, more than 1 PVC
morphology at baseline, and epicardial origin were associated
with a failure to achieve acute ablation success. Only
epicardial origin (OR: 6.9; 95% CI: 1.46 to 33.3; p ¼ 0.015)
and the presence of more than 1 PVC morphology in the
baseline Holter monitoring (OR: 6.2; 95% CI: 1.3 to 29.8;
p ¼ 0.022) were independent predictors in the multivariate
analysis (Online Tables 1 to 3).
Predictors of echocardiographic response. Table 4 shows
the univariate and multivariate analysis for the prediction of
echocardiographic response. Only SSA and baseline PVC
percentage predicted response. The other variables analyzed
were suspected SOO (right vs. left), epicardial origin, QRS
width, SHD etiology, and scar size in the ce-CMR. In
addition, neither the epicardial origin (3 [9%] in responders
vs 1 [5%] in nonresponders; p ¼ 0.97) nor the QRS width
(170  19 ms in responders vs. 175  19 ms in nonre-
sponders; p ¼ 0.41) were associated with the echocardio-
graphic response in the subgroup of patients with SSA.
Discussion
The present study describes the neurohormonal, echocar-
diographic, and clinical beneﬁt, and the recovery pattern of
consecutive patients with depressed LVEF and frequent
PVC submitted for ablation, regardless of the presence of
previously diagnosed SHD. This is also the ﬁrst series to
describe in depth the inﬂuence of PVC recurrences in
outcomes and timing, with 93% of recurrences occurring in
the ﬁrst 6 months. The ablation complexity of some PVCs,
depending on SOO, probably explains why SSA was ach-
ieved in only two-thirds of patients, along with a perhaps
higher recurrence rate in an unselected patient population
with a large proportion of patients having epicardial PVCs.
As a similar beneﬁt was obtained irrespective of knownultivariate Models
Univariate Multivariate
R (95% CI) p Value OR (95% CI) p Value
3 (1.29–8.92) 0.01
1 (0.97–1.05) 0.67
1 (1.05–1.17) <0.001 1.12 (1.06–1.18) <0.001
9 (0.96–1.01) 0.33
2 (0.45–2.81) 0.81
8 (0.51–5.63) 0.4
0 (0.90–6.40) 0.08 3.82 (1.09–13.32) 0.036
0 (0.65–4.43) 0.28
9 (0.89–1.11) 0.99
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1201SHD, the distinction between a “PVC-induced” cardio-
myopathy and a “PVC-worsened” cardiomyopathy does not
seem to be essential in selecting patients for PVC ablation.
In contrast, a higher baseline PVC burden was associated
with neurohormonal, echocardiographic, and clinical beneﬁt
and may be used to select patients. An important ﬁnding of
the study was the consistent temporal pattern of improve-
ment for all heart failure parameters; an early improvement
of BNP/NT pro-BNP levels, functional class, and LVEF
was observed and persisted after 6 months of follow-up.
PVC-induced or PVC-worsened cardiomyopathy. Alth-
ough there are several reports of reversible cardiomyopathy
after PVC ablation in patients with frequent PVC (1–8),
most studies have included only patients with suspected
PVC-induced cardiomyopathy; patients with known SHD
have been systematically excluded. The present study was
the ﬁrst to assess PVC ablation outcomes in unselected
patients with frequent PVCs and depressed LVEF. The
ﬁndings are clinically important because PVCs are fre-
quently observed in patients with SHD (14) and because
a reversible “PVC-worsened” cardiomyopathy is a concept
not yet deeply described and widely accepted. As a result,
many of these patients are not considered candidates for
RFCA. The present study suggests that they should be.
The improvement in LVEF observed in both groups,
with and without known SHD, is comparable to that re-
ported in previous studies (3,4) in selected patients with
PVC-induced cardiomyopathy. One-third of patients had
previously diagnosed SHD and their LVEF improvement
did not differ from that of patients with suspected PVC-
induced cardiomyopathy. That ﬁnding is consistent with
a report of signiﬁcant LVEF improvement after ablation of
frequent PVC in a series of 15 patients with previous
myocardial infarction (7). The authors suggested that the
depressed LV function is at least partly due to a reversible
cardiomyopathy in patients with more than 5% PVC at
baseline, despite the presence of scar tissue. The present
results support this hypothesis in a more heterogeneous
group of patients with heart diseases of different etiologies.
Interestingly, patients with previously diagnosed SHD as
well as patients with hyperenhancement in the CMR study
had a signiﬁcantly higher PVC burden at baseline and
a greater reduction of PVC percentage after SSA. This
phenomenon could be explained in part by a referral bias
(i.e., patients without a diagnosis of SHD are likely referred
earlier for PVC treatment). As PVC burden is an inde-
pendent predictor of response after ablation, this ﬁnding
may explain a similar beneﬁt after PVC ablation in patients
with and without SHD as well as the lack of inﬂuence of the
amount of scar in the response.
On the other hand, the small percentage of patients with
myocardial scar is in accordance with a previous report by
Sarrazin et al. (7), in which patients withmyocardial infarction
and frequent PVChad a smaller scar area in the ce-CMR than
patients without PVC with similar LVEF. This ﬁnding
suggests that a component of PVC-worsened LV dysfunctionis present. Further studies with a higher number of patients
having scar on ce-CMR are needed to establish its inﬂuence
on response after frequent PVC ablation.
Predictors of response. In the present study baseline PVC
percentage predicted response to RFCA. The PVC burden
necessary to induce or worsen LV dysfunction is not clearly
deﬁned. A burden as low as 4% was found to be associated
with cardiomyopathy (10). However, in another study the
majority of patients with PVC-induced cardiomyopathy
who improved after ablation had more than 10% PVC at
baseline (15). In the present study, the optimal cutoff value
in patients accepted for ablation was 13% PVC at baseline
to predict LVEF improvement of at least 5%. Importantly,
no patient with less than 13% baseline PVCs improved after
ablation. This is in line with the study of Baman et al. (15),
who reported that the lowest PVC burden resulting in
a reversible cardiomyopathy was 10% in patients with PVC-
induced cardiomyopathy.
Previous studies showed that an epicardial PVC origin as
well as the QRS width of PVC were predictors of a revers-
ible PVC-induced cardiomyopathy (16). In the present
study, neither right versus left SOO, nor epicardial origin,
nor QRS width were independent predictors of response.
Although the SOO (epicardial origin) was associated with
a lower rate of SSA, only the SSA was an independent
predictor of response, suggesting that the lack of PVC
burden reduction is the main variable to be taken into
account, rather than the SOO. Therefore, repeated Holter
monitoring could be recommended to check for SSA and
correctly interpret the response after ablation. Notably, any
recurrences are most likely to occur in the ﬁrst 6-month
period.
Finally, despite ablation of only the “dominant” PVC in
11 of the 20 patients with multiple morphologies at baseline,
this was not an independent predictor of SSA. This obser-
vation suggests that the elimination of all PVC morphol-
ogies may not be necessary.
ICD implantation. As a consequence of improvement in
heart failure parameters and the increase in LVEF, all
patients with 13% baseline PVC burden and SSA meeting
the indication criteria for primary prevention ICD implan-
tation prior of RFA had no such indication 6 months after
ablation. No sudden deaths or life-threatening ventricular
arrhythmias occurred in these patients during the 6-months
waiting period for re-evaluation nor during the entire
follow-up. In view of these results, and taking into account
that the 84  39% of the LVEF improvement was observed
in the ﬁrst 6 months after ablation, the 6-month reevalua-
tion interval after successful ablation seems to be a safe
approach. Whether an early evaluation for the presence of
PVC recurrences should be done remains to be determined.
Larger studies are needed to determine the length of the
period for which ICD implantation can be withheld safely.
Study limitations. The main limitation of this study is the
absence of a control group. A 24-h Holter monitoring may
be insufﬁcient to assess the exact PVC burden before and
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Use of antiarrhythmic drugs in patients without acute
successful ablation may affect the interpretation of the
results, although only two patients reached 80% reduction
of baseline PVC burden. The electrophysiological mecha-
nism of the ventricular arrhythmia was not systematically
studied, but could inﬂuence the ablation strategy and
recurrences if the PVC were related to scarring. Finally,
although the presence of scar seems not to be essential in
selecting patients for PVC ablation, it might inﬂuence the
degree of reverse remodeling. We cannot exclude the
possibility that LV dysfunction does not improve after PVC
elimination in patients with significant SHD and a large
myocardial scar. Further studies with a higher number of
patients having large scars on ce-CMR are needed to
establish any inﬂuence on response after frequent PVC
ablation.
Conclusions
Ablation of frequent PVC is associated with a progressive
neurohormonal, structural, and functional improvement in
unselected patients with depressed LVEF, regardless of
a potential PVC-induced or PVC-worsened cardiomyop-
athy. Improvement in LVEF was related to the baseline
PVC burden and the persistence of acute ablation success.
Given the magnitude of the obtained beneﬁt and its
consistency in unselected patients, all patients with
depressed LVEF should be evaluated for the presence of
frequent PVCs, especially those meeting criteria for primary
prevention ICD implantation, as the beneﬁt might inﬂuence
clinical decisions.
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APPENDIX
For more details on the methods of this study, please see the online version
of this paper.
